Bromocriptine is used to treat acromegaly and conditions associated with hyperprolactinemia like amenorrhea, infertility, and hypogonadism, prolactin-secreting adenomas; it is also used to prevent ovarian hyperstimulation syndrome. It was patented in 1968 and approved for medical use in 1975.. Reference standards of Bromocriptine API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
Bromocriptine
Catalogue No.:PA 02 49000
CAS :
Molecular Formula : C32H40BrN5O5
Molecular Weight : 654.59
2-Bromoanhydro-α-Ergocryptine
Catalogue No.:PA 02 49010
Molecular Formula : C32H38BrN5O4
Molecular Weight : 636.58
α-Ergocryptine
Catalogue No.:PA 02 49020
Molecular Formula : C32H41N5O5
Molecular Weight : 575.70
Bromocriptine Mesylate
Catalogue No.:PA 02 49510
Molecular Formula : C33H44BrN5O8S
Molecular Weight : 750.7
Paspalic Acid
Catalogue No.:PA 02 49520
Molecular Formula : C16H16N2O2
Molecular Weight : 268.31
Bromocriptine Mesylate (1076501)
Catalogue No.:PA USP1076501
Molecular Formula : NA
Molecular Weight : NA
bromocriptine mesilate (50RB)
Catalogue No.:PA BP50RB
Bromocriptine mesilate (B1150000)
Catalogue No.:PA EPB1150000
Bromocriptine mesilate for system suitability (Y0000677)
Catalogue No.:PA EPY0000677
(8S)-2-Bromo-α-ergocryptine
Catalogue No.:PA 02 49030
Molecular Weight : 654.61
(6aR,9R)-5-Bromo-N-[(2S,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2- methylpropyl)-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7- methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Catalogue No.:PA 02 49060
(6aR,9R)-5-Bromo-N-[(2R,5S,10aS,10bS)-10b-methoxy-2-(1-methylethyl)-5-(2- methylpropyl)-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Catalogue No.:PA 02 49070
Molecular Formula : C33H42BrN5O5
Molecular Weight : 668.63
Bromocriptine 2-Methylbutyl Analogue
Catalogue No.:PA 02 49530
(6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-2-((R)-sec-butyl)-10b-hydroxy-5-isobutyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Catalogue No.:PA 02 0491000
(6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4-nitroso-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Catalogue No.:PA 02 0491001
Molecular Formula : C32H39BrN6O6
Molecular Weight : 683.6
(6aR,6'aR,9R)-5-Bromo-N9,N9'-bis((2R,5S,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7,7'-dimethyl-4',6a,6',6'a,7,7',8,8',9,9'-decahydro-6H-[4,5'-biindolo[4,3-fg]quinoline]-9,9'-dicarboxamide
Catalogue No.:PA 02 0491002
Molecular Formula : C64H79BrN10O10
Molecular Weight : 1228.3
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
